Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $21

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $19 to $21.